Antidepressants and Pregnancy

Prenatal Valproic Acid (Depakote) Exposure Increases Risk for Neurodevelopmental Disorders

While we have considerable information regarding the teratogenic risk associated with prenatal exposure to various antiepileptic drugs (AEDs), we have considerably less information on the impact of exposure to AEDs on behavioral outcomes in [...]

Clinical Update 2020: Antipsychotic Medications and Risk of Gestational Diabetes

Given the number of younger women using atypical antipsychotic medications, there is an urgent need for more accurate data regarding the reproductive safety of these medications. One important question is whether these newer antipsychotic [...]

Risk of Preterm Birth and Respiratory Distress in Pregnancies with Prenatal Exposure to Antidepressants

From the OptumLabs Data Warehouse, researchers identified 226,932 singleton deliveries. Cases of antidepressant exposure were defined as pregnancies with prescription claims for antidepressants submitted between the last menstrual period and 35 weeks’ gestation.  To [...]

Neurodevelopmental Outcomes in Kindergartners with Prenatal Exposure to Antidepressants

While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]

Are Clinicians Using the PLLR to Guide Prescribing During Pregnancy?

In 2015, the U.S. Food and Drug Administration (FDA) proposed major revisions to prescription drug labeling -- the Pregnancy and Lactation Labeling Rule or PLLR -- in order to provide more accurate and helpful [...]

Go to Top